April 8, 2008 - BioChemics, Inc., a company “pioneering transdermal drug delivery,” announced it has entered into a research collaboration with Beth Israel Deaconess Medical Center (BIDMC) to evaluate the wound healing effects of some of the Company’s novel, proprietary formulations in preclinical models. BIDMC is one of the largest, most respected research hospitals in the country. BioChemics is a pharmaceutical company that has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE® (Vaso-active Lipid Encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents.Recent industry reports estimate the global wound care market to approach $12 billion by 2009, with a yearly growth rate in excess of 7%. US markets account for approximately half of the spending in this area. Indications for wound therapy and management include diabetes, age related skin or pressure ulcers, trauma and surgery... BioChemics' Press Release -
